阿加曲班治疗急性进展性脑梗死的效果探究

Efficacy of argatroban in the treatment of acute progressive cerebral infarction

目的探究阿加曲班治疗急性进展性脑梗死(APCI)的效果和安全性。方法抽取2020年1月至2022年8月河南科技大学附属许昌市中心医院收治的APCI患者92例,按照随机数字表法分为对照组与研究组,每组46例。对照组采用双抗等常规治疗,研究组在对照组的基础上采用阿加曲班治疗。对比两组治疗效果、凝血功能指标[纤维蛋白原(FIB)、凝血酶原时间(PT)、活化部分凝血酶原时间(APTT)]、美国国立卫生研究院卒中量表(NIHSS)评分、肢体功能[Fugl-Meyer评定量表(FMA)评分]及不良反应发生率。结果研究组总有效率(93.48%,43/46)高于对照组(82.61%,38/46),P<0.05。治疗后,研究组FIB低于对照组,PT、APTT高于对照组(P<0.05);治疗后,研究组NIHSS评分低于对照组,FMA评分高于对照组(P<0.05)。研究组不良反应发生率(6.52%,3/46)与对照组(4.35%,2/46)比较差异未见统计学意义(P>0.05)。结论阿加曲班治疗APCI效果显著,能改善患者凝血功能,促进患者神经功能缺损早期康复,提高患者运动功能,改善生活质量,且未增加不良反应发生率。

Objective To investigate the efficacy and safety of argatroban in the treatment of acute progressive cerebral infarction(APCI).Methods A total of 92 patients with APCI treated in Xuchang Central Hospital Affiliated to Henan University of Science and Technology from January 2020 to August 2022 were selected and divided into control group and study group by random number table method,with 46 cases in each group.The control group received conventional dual antiplatelet therapy,and the study group received argatroban treatment based on the treatment of the control group.The efficacy,coagulation function indicators,including fibrinogen(FIB),prothrombin time(PT)and activated partial thromboplastin time(APTT),National Institutes of Health stroke scale(NIHSS)score,limb function assessed by Fugl-Meyer assessment scale(FMA)score,and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the study group(93.48%,43/46)was higher than that of the control group(82.61%,38/46),P<0.05.After treatment,the study group had lower FIB,higher PT and higher APTT than the control group after treatment(P<0.05).Compared with the control group,the study group had lower NIHSS score and higher FMA score after treatment(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group(6.52%,3/46)and the control group(4.35%,2/46),P>0.05.Conclusions Argatroban has a significant effect in the treatment of APCI,which can improve coagulation function,early recovery of nerve function,limb motor function and quality of life,without increasing incidence of adverse reactions.